3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Recurrence
2
Wilms Tumor
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pseudomyxoma Peritonei
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Melanoma
1
Lymphoma, B-Cell
1
Lymphoma
1
Kidney Transplantation
1
Digestive System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Adenocarcinoma, Clear Cell
1
Interventions
Mitomycin
2
tislelizumab
1
molgramostim
1
cryoprecipitate coagulum
1
Tacrolimus
1
Standard of Care
1
Specimen Handling
1
Sirolimus
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Hyperthermic Intraperitoneal Chemotherapy
1
Fluorouracil
1
CTLA-4 Antigen
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pseudomyxoma Peritonei
×
Alemtuzumab
×
1 year
×
Clear all
NCT06084780
2026-04-09
TRANSCAPE
Case Comprehensive Cancer Center
Phase 2
Not yet recruiting
20 enrolled